软肝消癥胶囊治疗肝炎肝纤维化的临床观察

目的:观察自拟经验方软肝消症胶囊对肝炎肝纤维化的临床疗效。方法:将慢性乙型肝炎66例和肝炎后肝硬化34例患者随机分为治疗组和对照组,检测治疗前和治疗4个月后的血清肝纤维化四项指标(HA、LN、PⅢP、IV-C)的变化,部分病人进行肝脾彩色多普勒超声检查(CDFI),观测门静脉主干内径、门静脉血流速度、脾静脉内径及脾厚度在治疗2个疗程前后的变化。结果:两组治疗后肝纤维化四项指标均有改善,但治疗组明显优于对照组。治疗组门静脉主于内径、脾静脉内径变窄,门静脉血流速度增快,与对照组比较其差异具有统计学意义(P<0.01)。结论:软肝消症胶囊可改善肝纤维化四项指标,对肝纤维化的治疗有较好的临床疗效。

Clinical Observation of the Hepatic Fibrosis of Hepatitis B Treated by Ruangan Xiaozheng Capsule

Objective: To observe the clinical effect of Ruangan Xiaozheng capsule in the treatment of patients with the hepatic fibrosis of hepatitis. Methods: 66 cases of hepatitis B and 34 cases of posthepatitic cirrhosis have been divided into therapy group and control group. To detect the changes of the serum four indexes of hepatofibrosis (HA, LN, PIIIP, IV-C) before and after four month therapy. And some patients checked the CDFI of liver and spleen. Result: Four indexes of hepatofibrosis were ameliorated in two groups, and the therapy group was better than the control group. The bore of portal vein primary shaf and splenic vein checked by the CDFI had been narrowed and the flow-rate went been faster after therapy, the therapy group were better than the control group (P<0.01). Conclusion: The Ruangan Xiaozheng capsule can ameliorated the four indexes of hepatofibrosis and had exactly clinic effect in treatment of hepatic fibrosis.